Treatment course
LIVER METASTASIS, DISEASE PROGRESSION
All 19 patients received two cycles of gemcitabine and nab‐paclitaxel. One developed rapid CA19‐9 rise and subsequent liver metastasis at first restaging time point after two cycles of chemotherapy. Another one relocated and ended the study prematurely. One proceeded with chemoradiation but was unable to complete it due to functional decline that was retrospectively suspected to be disease progression, but this was unconfirmed. Sixteen patients completed the intended chemoradiation phase of treatment with either 5‐fluorouracil or capecitabine (Figure Consort diagram.